MENY

Gällande vårdprogram bukspottkörtelcancer

Fastställt av Regionala cancercentrum i samverkan 2017-12-07.

22. Referenser

1.Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725-36.

2.Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114-7.

3.Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol. 2013;24(3):792-800.

4.Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607-20.

5.Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393(4):535-45.

6.Luo J, Ye W, Zendehdel K, Adami J, Adami HO, Boffetta P, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet. 2007;369(9578):2015-20.

7.Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. British journal of cancer. 2003;89(3):519-23.

8.Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076-83.

9.Genkinger JM, Spiegelman D, Anderson KE, Bergkvist L, Bernstein L, van den Brandt PA, et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009;18(3):765-76.

10.Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328(20):1433-7.

11.Jacobs EJ, Chanock SJ, Fuchs CS, Lacroix A, McWilliams RR, Steplowski E, et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer. 2010;127(6):1421-8.

12.http://www.socialstyrelsen.se/nationellariktlinjerforsjukdomsforebyggandemetoder/.

13.Meyskens FL, Jr., Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, et al. Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst. 2016;108(2).

14.Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15(1):8-18.

15.Raimondi S, Maisonneuve P, Lohr JM, Lowenfels AB. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1894-7.

16.Barone E, Corrado A, Gemignani F, Landi S. Environmental risk factors for pancreatic cancer: an update. Arch Toxicol. 2016;90(11):2617-42.

17.Haas SL, Ye W, Lohr JM. Alcohol consumption and digestive tract cancer. Curr Opin Clin Nutr Metab Care. 2012;15(5):457-67.

18.Genetik, S. F. f. M. (2012, 2012-11-23). "Utredning, uppföljning och omhändertagande av personer med misstänkt ärftlig ökad risk för tumörsjukdom - Pankreascancer."   Retrieved 2017-01-05, 2017, from http://sfmg.se/download/riktlinjer/Cancergenetik/Hereditar_pankreascancer_SOTA_november_2012.pdf.

19.Ahmed Ali U, Jens S, Busch OR, Keus F, van Goor H, Gooszen HG, et al. Antioxidants for pain in chronic pancreatitis. Cochrane Database Syst Rev. 2014(8):CD008945.

20.Hemminki K, Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer. 2003;103(4):525-30.

21.Pittman ME, Brosens LA, Wood LD. Genetic Syndromes with Pancreatic Manifestations. Surg Pathol Clin. 2016;9(4):705-15.

22.Del Chiaro M, Zerbi A, Falconi M, Bertacca L, Polese M, Sartori N, et al. Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology. 2007;7(5-6):459-69.

23.Brune KA, Lau B, Palmisano E, Canto M, Goggins MG, Hruban RH, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010;102(2):119-26.

24.Capurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW, et al. Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World J Gastrointest Endosc. 2015;7(9):833-42.

25.Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996;14(2):141-5.

26.Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK, Jr., Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89(6):442-6.

27.Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol. 2010;24(3):349-58.

28.Ying L, Lin X, Xie ZL, Hu YP, Tang KF, Shi KQ. Clinical utility of endoscopic ultrasound elastography for identification of malignant pancreatic masses: a meta-analysis. J Gastroenterol Hepatol. 2013;28(9):1434-43.

29.Del Chiaro M, Verbeke CS, Kartalis N, Pozzi Mucelli R, Gustafsson P, Hansson J, et al. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. JAMA Surg. 2015;150(6):512-8.

30.Jais B, Rebours V, Malleo G, Salvia R, Fontana M, Maggino L, et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut. 2016;65(2):305-12.

31.Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control. 2008;15(4):280-7.

32.Wada K, Takaori K, Traverso LW. Screening for Pancreatic Cancer. Surg Clin North Am. 2015;95(5):1041-52.

33.Arnelo U, Siiki A, Swahn F, Segersvard R, Enochsson L, del Chiaro M, et al. Single-operator pancreatoscopy is helpful in the evaluation of suspected intraductal papillary mucinous neoplasms (IPMN). Pancreatology. 2014;14(6):510-4.

34.Lohr JM, Lonnebro R, Stigliano S, Haas SL, Swahn F, Enochsson L, et al. Outcome of probe-based confocal laser endomicroscopy (pCLE) during endoscopic retrograde cholangiopancreatography: A single-center prospective study in 45 patients. United European Gastroenterol J. 2015;3(6):551-60.

35.Fendrich V, Langer P, Bartsch DK. Familial pancreatic cancer--status quo. Int J Colorectal Dis. 2014;29(2):139-45.

36.Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, et al. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discov. 2016;6(2):166-75.

37.Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64(7):2634-8.

38.McWilliams RR, Maisonneuve P, Bamlet WR, Petersen GM, Li D, Risch HA, et al. Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis. Pancreas. 2016;45(2):311-6.

39.Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. J Clin Oncol. 2016;34(17):2010-9.

40.Ibrahim IS, Bonsing BA, Swijnenburg RJ, Welling L, Veenendaal RA, Wasser MN, et al. Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer. Fam Cancer. 2017;16(1):111-5.

41.Bartsch DK, Slater EP, Carrato A, Ibrahim IS, Guillen-Ponce C, Vasen HF, et al. Refinement of screening for familial pancreatic cancer. Gut. 2016;65(8):1314-21.

42.Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124(5):1292-9.

43.Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 2008;191(3):802-7.

44.de Jong K, Nio CY, Hermans JJ, Dijkgraaf MG, Gouma DJ, van Eijck CH, et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol. 2010;8(9):806-11.

45.Zhang XM, Mitchell DG, Dohke M, Holland GA, Parker L. Pancreatic cysts: depiction on single-shot fast spin-echo MR images. Radiology. 2002;223(2):547-53.

46.Belyaev O, Seelig MH, Muller CA, Tannapfel A, Schmidt WE, Uhl W. Intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol. 2008;42(3):284-94.

47.Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183-97.

48.Del Chiaro M, Verbeke C, Salvia R, Kloppel G, Werner J, McKay C, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. 2013;45(9):703-11.

49.Levy A, Popovici T, Bories PN. Tumor markers in pancreatic cystic fluids for diagnosis of malignant cysts. Int J Biol Markers. 2017;32(3):e291-e6.

50.Oh SH, Lee JK, Lee KT, Lee KH, Woo YS, Noh DH. The Combination of Cyst Fluid Carcinoembryonic Antigen, Cytology and Viscosity Increases the Diagnostic Accuracy of Mucinous Pancreatic Cysts. Gut Liver. 2017;11(2):283-9.

51.Nagashio Y, Hijioka S, Mizuno N, Hara K, Imaoka H, Bhatia V, et al. Combination of cyst fluid CEA and CA 125 is an accurate diagnostic tool for differentiating mucinous cystic neoplasms from intraductal papillary mucinous neoplasms. Pancreatology. 2014;14(6):503-9.

52.Hackert T, Fritz S, Klauss M, Bergmann F, Hinz U, Strobel O, et al. Main-duct Intraductal Papillary Mucinous Neoplasm: High Cancer Risk in Duct Diameter of 5 to 9 mm. Ann Surg. 2015;262(5):875-80; discussion 80-1.

53.Del Chiaro M, Ateeb Z, Hansson MR, Rangelova E, Segersvard R, Kartalis N, et al. Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas (IPMN) Under Surveillance: A Single-Institution Experience. Ann Surg Oncol. 2016.

54.Sawai Y, Yamao K, Bhatia V, Chiba T, Mizuno N, Sawaki A, et al. Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. Endoscopy. 2010;42(12):1077-84.

55.Del Chiaro M, Ateeb Z, Hansson MR, Rangelova E, Segersvard R, Kartalis N, et al. Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas (IPMN) Under Surveillance: A Single-Institution Experience. Ann Surg Oncol. 2017;24(4):1120-6.

56.Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738-53.

57.Matthaei H, Norris AL, Tsiatis AC, Olino K, Hong SM, dal Molin M, et al. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2012;255(2):326-33.

58.Bhardwaj N, Dennison AR, Maddern GJ, Garcea G. Management implications of resection margin histology in patients undergoing resection for IPMN: A meta-analysis. Pancreatology. 2016;16(3):309-17.

59.Pea A, Yu J, Rezaee N, Luchini C, He J, Dal Molin M, et al. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Ann Surg. 2016.

60.Wilentz RE SR, Hruban RH. Screening of pancreatic cancer using techniques to detect altered gene products. In Pancreatic cancer, pathogenesis, diagnosis, and treatment. . Ed Reber HE, Humana Press 1998:pp 113-36.

61.Ihse I, Isaksson G. Pancreatic carcinoma: diagnosis and treatment. Clin Gastroenterol. 1984;13(3):961-84.

62.Warren KW, Christophi C, Armendariz R, Basu S. Current trends in the diagnosis and treatment of carcinoma of the pancreas. Am J Surg. 1983;145(6):813-8.

63.Bakkevold KE, Arnesjo B, Kambestad B. Carcinoma of the pancreas and papilla of Vater: presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective multicentre trial in 472 patients. Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol. 1992;27(4):317-25.

64.Klinkenbijl JH, Jeekel J, Schmitz PI, Rombout PA, Nix GA, Bruining HA, et al. Carcinoma of the pancreas and periampullary region: palliation versus cure. Br J Surg. 1993;80(12):1575-8.

65.Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open. 2014;4(11):e005720.

66.Watanabe I, Sasaki S, Konishi M, Nakagohri T, Inoue K, Oda T, et al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas. 2004;28(2):160-5.

67.Iodice S, Gandini S, Lohr M, Lowenfels AB, Maisonneuve P. Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost. 2008;6(5):781-8.

68.RCC i samverkan. Cancer i bukspottkörteln och periampullärt. Beskrivning av standardiserat vårdförlopp. 2015.  http://www.cancercentrum.se/samverkan/cancerdiagnoser/bukspottkortel/vardforlopp-bukspottkortel/gallande-vardforlopp2.

69.Modha K. Clinical Approach to Patients With Obstructive Jaundice. Tech Vasc Interv Radiol. 2015;18(4):197-200.

70.Kinney T. Evidence-based imaging of pancreatic malignancies. Surg Clin North Am. 2010;90(2):235-49.

71.Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20(24):7864-77.

72.Pietryga JA, Morgan DE. Imaging preoperatively for pancreatic adenocarcinoma. J Gastrointest Oncol. 2015;6(4):343-57.

73.Shrikhande SV, Barreto SG, Goel M, Arya S. Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature. HPB (Oxford). 2012;14(10):658-68.

74.Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008;6(12):1301-8.

75.Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR. Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol. 2008;23(1):23-33.

76.Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, et al. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007;18 Suppl 7:vii1-vii10.

77.Ichikawa T, Erturk SM, Sou H, Nakajima H, Tsukamoto T, Motosugi U, et al. MDCT of pancreatic adenocarcinoma: optimal imaging phases and multiplanar reformatted imaging. AJR Am J Roentgenol. 2006;187(6):1513-20.

78.Brugel M, Link TM, Rummeny EJ, Lange P, Theisen J, Dobritz M. Assessment of vascular invasion in pancreatic head cancer with multislice spiral CT: value of multiplanar reconstructions. Eur Radiol. 2004;14(7):1188-95.

79.Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB, Jr. MDCT in Pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. AJR Am J Roentgenol. 2004;182(2):419-25.

80.Prokesch RW, Chow LC, Beaulieu CF, Bammer R, Jeffrey RB, Jr. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology. 2002;224(3):764-8.

81.Kim JH, Park SH, Yu ES, Kim MH, Kim J, Byun JH, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology. 2010;257(1):87-96.

82.Ansari NA, Ramalho M, Semelka RC, Buonocore V, Gigli S, Maccioni F. Role of magnetic resonance imaging in the detection and characterization of solid pancreatic nodules: An update. World J Radiol. 2015;7(11):361-74.

83.Fulcher AS, Turner MA, Capps GW, Zfass AM, Baker KM. Half-Fourier RARE MR cholangiopancreatography: experience in 300 subjects. Radiology. 1998;207(1):21-32.

84.Ichikawa T, Sou H, Araki T, Arbab AS, Yoshikawa T, Ishigame K, et al. Duct-penetrating sign at MRCP: usefulness for differentiating inflammatory pancreatic mass from pancreatic carcinomas. Radiology. 2001;221(1):107-16.

85.Fattahi R, Balci NC, Perman WH, Hsueh EC, Alkaade S, Havlioglu N, et al. Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging. 2009;29(2):350-6.

86.Kartalis N, Lindholm TL, Aspelin P, Permert J, Albiin N. Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur Radiol. 2009;19(8):1981-90.

87.Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS, Crownhart BS, et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol. 2004;182(4):897-903.

88.Yasuda I, Iwashita T, Doi S, Nakashima M, Moriwaki H. Role of EUS in the early detection of small pancreatic cancer. Dig Endosc. 2011;23 Suppl 1:22-5.

89.Puli SR, Bechtold ML, Buxbaum JL, Eloubeidi MA. How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass?: A meta-analysis and systematic review. Pancreas. 2013;42(1):20-6.

90.Pappas SG, Christians KK, Tolat PP, Mautz AP, Lal A, McElroy L, et al. Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? HPB (Oxford). 2014;16(1):70-4.

91.Cascinu S, Falconi M, Valentini V, Jelic S, Group EGW. Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v55-8.

92.Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol. 2013;19(29):4808-17.

93.Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CH. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol. 2014;40(7):794-804.

94.Kauhanen SP, Komar G, Seppanen MP, Dean KI, Minn HR, Kajander SA, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250(6):957-63.

95.Quon A, Chang ST, Chin F, Kamaya A, Dick DW, Loo BW, Jr., et al. Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur J Nucl Med Mol Imaging. 2008;35(3):527-31.

96.Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsoe CP, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013;39(2):187-210.

97.Guang Y, Xie L, Ding H, Cai A, Huang Y. Diagnosis value of focal liver lesions with SonoVue(R)-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: a meta-analysis. J Cancer Res Clin Oncol. 2011;137(11):1595-605.

98.Holalkere NS, Sahani DV, Blake MA, Halpern EF, Hahn PF, Mueller PR. Characterization of small liver lesions: Added role of MR after MDCT. J Comput Assist Tomogr. 2006;30(4):591-6.

99.Motosugi U, Ichikawa T, Morisaka H, Sou H, Muhi A, Kimura K, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology. 2011;260(2):446-53.

100.Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2016;7:CD009323.

101.Rumstadt B, Schwab M, Schuster K, Hagmuller E, Trede M. The role of laparoscopy in the preoperative staging of pancreatic carcinoma. J Gastrointest Surg. 1997;1(3):245-50.

102.Beigelman-Aubry C, Hill C, Grenier PA. Management of an incidentally discovered pulmonary nodule. Eur Radiol. 2007;17(2):449-66.

103.Nordback I, Saaristo R, Piironen A, Sand J. Chest computed tomography in the staging of pancreatic and periampullary carcinoma. Scand J Gastroenterol. 2004;39(1):81-6.

104.Bipat S, Phoa SS, van Delden OM, Bossuyt PM, Gouma DJ, Lameris JS, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr. 2005;29(4):438-45.

105.Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology. 2014;270(1):248-60.

106.Brook OR, Brook A, Vollmer CM, Kent TS, Sanchez N, Pedrosa I. Structured reporting of multiphasic CT for pancreatic cancer: potential effect on staging and surgical planning. Radiology. 2015;274(2):464-72.

107.Prenzel KL, Holscher AH, Vallbohmer D, Drebber U, Gutschow CA, Monig SP, et al. Lymph node size and metastatic infiltration in adenocarcinoma of the pancreatic head. Eur J Surg Oncol. 2010;36(10):993-6.

108.Amin MB, et al AUCC  Cancer Staging Manual  8th Edition 2016 

109.Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1751-6.

110.Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.

111.Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035-46.

112.Nakayama Y, Yamashita Y, Kadota M, Takahashi M, Kanemitsu K, Hiraoka T, et al. Vascular encasement by pancreatic cancer: correlation of CT findings with surgical and pathologic results. J Comput Assist Tomogr. 2001;25(3):337-42.

113.Schima W, Ba-Ssalamah A, Kolblinger C, Kulinna-Cosentini C, Puespoek A, Gotzinger P. Pancreatic adenocarcinoma. Eur Radiol. 2007;17(3):638-49.

114.Mazzeo S, Cappelli C, Caramella D, Del Chiaro M, Campani D, Pollina L, et al. Evaluation of vascular infiltration in resected patients for pancreatic cancer: comparison among multidetector CT, intraoperative findings and histopathology. Abdom Imaging. 2007;32(6):737-42.

115.Springett GM, Hoffe SE. Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control. 2008;15(4):295-307.

116.Valls C, Andia E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol. 2002;178(4):821-6.

117.Mazzeo S, Cappelli C, Battaglia V, Caramella D, Caproni G, Pontillo Contillo B, et al. Multidetector CT in the evaluation of retroperitoneal fat tissue infiltration in ductal adenocarcinoma of the pancreatic head: correlation with histopathological findings. Abdom Imaging. 2010;35(4):465-70.

118.Wellner UF, Krauss T, Csanadi A, Lapshyn H, Bolm L, Timme S, et al. Mesopancreatic Stromal Clearance Defines Curative Resection of Pancreatic Head Cancer and Can Be Predicted Preoperatively by Radiologic Parameters: A Retrospective Study. Medicine (Baltimore). 2016;95(3):e2529.

119.Loizou L, Albiin N, Ansorge C, Andersson M, Segersvard R, Leidner B, et al. Computed tomography staging of pancreatic cancer: a validation study addressing interobserver agreement. Pancreatology. 2013;13(6):570-5.

120.Network NCC. Pancreatic Adenocarcinoma (Version 2.2016) 2016, https://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf.

121.Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727-33.

122.Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Buchler MW, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254(6):882-93.

123.Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19(2):182-6.

124.Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol. 2005;23(20):4524-31.

125.Bunger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137(3):375-89.

126.Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266-70.

127.Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21(3):441-7.

128.Abdel-Misih SR, Hatzaras I, Schmidt C, Saab TB, Klemanski D, Muscarella P, et al. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Ann Surg Oncol. 2011;18(4):1116-21.

129.Micke O, Bruns F, Schafer U, Kurowski R, Horst E, Willich N. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res. 2003;23(2A):835-40.

130.Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89(8):1413-7.

131.Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24(18):2897-902.

132.Ong SL, Garcea G, Pollard CA, Furness PN, Steward WP, Rajesh A, et al. A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology. 2009;9(5):583-600.

133.Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18 Suppl 1:S17-25.

134.Hartwig W, Schneider L, Diener MK, Bergmann F, Buchler MW, Werner J. Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg. 2009;96(1):5-20.

135.Yoshinaga S, Suzuki H, Oda I, Saito Y. Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses. Dig Endosc. 2011;23 Suppl 1:29-33.

136.Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc. 2012;75(2):319-31.

137.Chong A, Venugopal K, Segarajasingam D, Lisewski D. Tumor seeding after EUS-guided FNA of pancreatic tail neoplasia. Gastrointest Endosc. 2011;74(4):933-5.

138.Micames C, Jowell PS, White R, Paulson E, Nelson R, Morse M, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc. 2003;58(5):690-5.

139.Dumonceau JM, Polkowski M, Larghi A, Vilmann P, Giovannini M, Frossard JL, et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2011;43(10):897-912.

140.Karlson BM, Forsman CA, Wilander E, Skogseid B, Lindgren PG, Jacobson G, et al. Efficiency of percutaneous core biopsy in pancreatic tumor diagnosis. Surgery. 1996;120(1):75-9.

141.Zamboni G, Luttges J, Capelli P, Frulloni L, Cavallini G, Pederzoli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch. 2004;445(6):552-63.

142.D'Onofrio M, Zamboni G, Tognolini A, Malago R, Faccioli N, Frulloni L, et al. Mass-forming pancreatitis: value of contrast-enhanced ultrasonography. World J Gastroenterol. 2006;12(26):4181-4.

143.Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58(11):1504-7.

144.Keulers BJ, Scheltinga MR, Houterman S, Van Der Wilt GJ, Spauwen PH. Surgeons underestimate their patients' desire for preoperative information. World J Surg. 2008;32(6):964-70.

145.Lithner, M. and T. Zilling, Does preoperative information increase the wellbeing of the patient after surgery? (in Swedish). Vård i Norden 1998; 18:31-33,39, 1998.

146.Ethun CG, Kooby DA. The importance of surgical margins in pancreatic cancer. J Surg Oncol. 2016;113(3):283-8.

147.Markov P, Satoi S, Kon M. Redefining the R1 resection in patients with pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016;23(9):523-32.

148.Verbeke CS. Resection margins and R1 rates in pancreatic cancer--are we there yet? Histopathology. 2008;52(7):787-96.

149.Campbell, Verbeke, Pathology of the Pancreas, Springer, 2013.

150.KVAST-dokument för pankreas och periampullära regionen. http://www.svfp.se/node/281.

151.Bosman FT,  Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System, 4th edition. International Agency for Research on Cancer, Lyon,2010.

152.Washington K, Berlin J, Branton P et al. Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas. Northfield, IL: College of American Pathologists; 2010.

153.van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362(2):129-37.

154.Wang Q, Gurusamy KS, Lin H, Xie X, Wang C. Preoperative biliary drainage for obstructive jaundice. Cochrane Database Syst Rev. 2008(3):CD005444.

155.Boulay BR, Gardner TB, Gordon SR. Occlusion rate and complications of plastic biliary stent placement in patients undergoing neoadjuvant chemoradiotherapy for pancreatic cancer with malignant biliary obstruction. J Clin Gastroenterol. 2010;44(6):452-5.

156.Tsuboi T, Sasaki T, Serikawa M, Ishii Y, Mouri T, Shimizu A, et al. Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery. Gastroenterol Res Pract. 2016;2016:7968201.

157.Barkun AN, Adam V, Martel M, AlNaamani K, Moses PL. Partially covered self-expandable metal stents versus polyethylene stents for malignant biliary obstruction: a cost-effectiveness analysis. Can J Gastroenterol Hepatol. 2015;29(7):377-83.

158.Mullen JT, Lee JH, Gomez HF, Ross WA, Fukami N, Wolff RA, et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg. 2005;9(8):1094-104; discussion 104-5.

159.Zorron Pu L, de Moura EG, Bernardo WM, Baracat FI, Mendonca EQ, Kondo A, et al. Endoscopic stenting for inoperable malignant biliary obstruction: A systematic review and meta-analysis. World J Gastroenterol. 2015;21(47):13374-85.

160.Chandrashekhara SH, Gamanagatti S, Singh A, Bhatnagar S. Current Status of Percutaneous Transhepatic Biliary Drainage in Palliation of Malignant Obstructive Jaundice: A Review. Indian J Palliat Care. 2016;22(4):378-87.

161.Gregoratos G. Current guideline-based preoperative evaluation provides the best management of patients undergoing noncardiac surgery. Circulation. 2008;117(24):3134-44; discussion 

162.De Hert S, Imberger G, Carlisle J, Diemunsch P, Fritsch G, Moppett I, et al. Preoperative evaluation of the adult patient undergoing non-cardiac surgery: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2011;28(10):684-722.

163.Reilly DF, McNeely MJ, Doerner D, Greenberg DL, Staiger TO, Geist MJ, et al. Self-reported exercise tolerance and the risk of serious perioperative complications. Arch Intern Med. 1999;159(18):2185-92.

164.Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, De Hert S, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2014;31(10):517-73.

165.Guarracino F, Baldassarri R, Priebe HJ. Revised ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Implications for preoperative clinical evaluation. Minerva Anestesiol. 2015;81(2):226-33.

166.Scott IA, Shohag HA, Kam PC, Jelinek MV, Khadem GM. Preoperative cardiac evaluation and management of patients undergoing elective non-cardiac surgery. Med J Aust. 2013;199(10):667-73.

167.Huttner FJ, Klotz R, Ulrich A, Buchler MW, Diener MK. Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy. Cochrane Database Syst Rev. 2016;9:CD011862.

168.Lin PW, Lin YJ. Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy. Br J Surg. 1999;86(5):603-7.

169.Peng SY, Wang JW, Lau WY, Cai XJ, Mou YP, Liu YB, et al. Conventional versus binding pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. Ann Surg. 2007;245(5):692-8.

170.Buc E, Flamein R, Golffier C, Dubois A, Nagarajan G, Futier E, et al. Peng's binding pancreaticojejunostomy after pancreaticoduodenectomy: a French prospective study. J Gastrointest Surg. 2010;14(4):705-10.

171.Casadei R, Ricci C, Silvestri S, Campra D, Ercolani G, D'Ambra M, et al. Peng's binding pancreaticojejunostomy after pancreaticoduodenectomy. An Italian, prospective, dual-institution study. Pancreatology. 2013;13(3):305-9.

172.Guerrini GP, Soliani P, D'Amico G, Di Benedetto F, Negri M, Piccoli M, et al. Pancreaticojejunostomy Versus Pancreaticogastrostomy After Pancreaticoduodenectomy: An Up-to-date Meta-Analysis. J Invest Surg. 2016;29(3):175-84.

173.Zhou Y, Yu J, Wu L, Li B. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy on occurrences of postoperative pancreatic fistula after pancreaticoduodenectomy. Asian J Surg. 2015;38(3):155-60.

174.Que W, Fang H, Yan B, Li J, Guo W, Zhai W, et al. Pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Am J Surg. 2015;209(6):1074-82.

175.Xiong JJ, Tan CL, Szatmary P, Huang W, Ke NW, Hu WM, et al. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Br J Surg. 2014;101(10):1196-208.

176.Crippa S, Cirocchi R, Randolph J, Partelli S, Belfiori G, Piccioli A, et al. Pancreaticojejunostomy is comparable to pancreaticogastrostomy after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. Langenbecks Arch Surg. 2016;401(4):427-37.

177.Keck T, Wellner UF, Bahra M, Klein F, Sick O, Niedergethmann M, et al. Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): Perioperative and Long-term Results of a Multicenter Randomized Controlled Trial. Ann Surg. 2016;263(3):440-9.

178.Cheng Y, Ye M, Xiong X, Peng S, Wu HM, Cheng N, et al. Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. Cochrane Database Syst Rev. 2016;2:CD009621.

179.Shukla PJ, Barreto SG, Fingerhut A. Do transanastomotic pancreatic ductal stents after pancreatic resections improve outcomes? Pancreas. 2010;39(5):561-6.

180.Xiong JJ, Altaf K, Mukherjee R, Huang W, Hu WM, Li A, et al. Systematic review and meta-analysis of outcomes after intraoperative pancreatic duct stent placement during pancreaticoduodenectomy. Br J Surg. 2012;99(8):1050-61.

181.Markar SR, Vyas S, Karthikesalingam A, Imber C, Malago M. The impact of pancreatic duct drainage following pancreaticojejunostomy on clinical outcome. J Gastrointest Surg. 2012;16(8):1610-7.

182.Gurusamy KS, Kumar S, Davidson BR. Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. Cochrane Database Syst Rev. 2013(2):CD008533.

183.Huttner FJ, Mihaljevic AL, Hackert T, Ulrich A, Buchler MW, Diener MK. Effectiveness of Tachosil((R)) in the prevention of postoperative pancreatic fistula after distal pancreatectomy: a systematic review and meta-analysis. Langenbecks Arch Surg. 2016;401(2):151-9.

184.Qian D, Lu Z, Jackson R, Wu J, Liu X, Cai B, et al. Effect of antecolic or retrocolic route of gastroenteric anastomosis on delayed gastric emptying after pancreaticoduodenectomy: A meta-analysis of randomized controlled trials. Pancreatology. 2016;16(1):142-50.

185.Pedrazzoli S, Beger HG, Obertop H, Andren-Sandberg A, Fernandez-Cruz L, Henne-Bruns D, et al. A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer. Dig Surg. 1999;16(4):337-45.

186.Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156(3):591-600.

187.Michalski CW, Kleeff J, Wente MN, Diener MK, Buchler MW, Friess H. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg. 2007;94(3):265-73.

188.Farnell MB, Aranha GV, Nimura Y, Michelassi F. The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence. J Gastrointest Surg. 2008;12(4):651-6.

189.Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 2012;19(3):230-41.

190.Sierzega M, Popiela T, Kulig J, Nowak K. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas. 2006;33(3):240-5.

191.Yamada S, Fujii T, Hirakawa A, Kanda M, Sugimoto H, Kodera Y. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Langenbecks Arch Surg. 2016;401(8):1143-52.

192.Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141(5):610-8.

193.House MG, Gonen M, Jarnagin WR, D'Angelica M, DeMatteo RP, Fong Y, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11(11):1549-55.

194.Yamada S, Nakao A, Fujii T, Sugimoto H, Kanazumi N, Nomoto S, et al. Pancreatic cancer with paraaortic lymph node metastasis: a contraindication for radical surgery? Pancreas. 2009;38(1):e13-7.

195.Pavlidis TE, Pavlidis ET, Sakantamis AK. Current opinion on lymphadenectomy in pancreatic cancer surgery. Hepatobiliary Pancreat Dis Int. 2011;10(1):21-5.

196.Kanda M, Fujii T, Nagai S, Kodera Y, Kanzaki A, Sahin TT, et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas. 2011;40(6):951-5.

197.Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232-7.

198.Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009;11(1):18-24.

199.Verbeke CS. Resection margins in pancreatic cancer: are we entering a new era? HPB (Oxford). 2014;16(1):1-2.

200.Delpero JR, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford). 2014;16(1):20-33.

201.Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36(4):884-91.

202.Chua TC, de Reuver PR, Staerkle RF, Neale ML, Arena J, Mittal A, et al. Transverse closure of mesenterico-portal vein after vein resection in pancreatoduodenectomy. Eur J Surg Oncol. 2016;42(2):211-8.

203.Fukuda S, Oussoultzoglou E, Bachellier P, Rosso E, Nakano H, Audet M, et al. Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma. Arch Surg. 2007;142(2):172-9; discussion 80.

204.Boggi U, Del Chiaro M, Croce C, Vistoli F, Signori S, Moretto C, et al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery. 2009;146(5):869-81.

205.Kaneoka Y, Yamaguchi A, Isogai M. Portal or superior mesenteric vein resection for pancreatic head adenocarcinoma: prognostic value of the length of venous resection. Surgery. 2009;145(4):417-25.

206.Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8):935-49; discussion 49-50.

207.Muller SA, Hartel M, Mehrabi A, Welsch T, Martin DJ, Hinz U, et al. Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg. 2009;13(4):784-92.

208.Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, et al. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg. 2014;218(3):401-11.

209.Yekebas EF, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist YK, et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg. 2008;247(2):300-9.

210.Nakao A, Takeda S, Inoue S, Nomoto S, Kanazumi N, Sugimoto H, et al. Indications and techniques of extended resection for pancreatic cancer. World J Surg. 2006;30(6):976-82; discussion 83-4.

211.Nakao A, Kanzaki A, Fujii T, Kodera Y, Yamada S, Sugimoto H, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg. 2012;255(1):103-8.

212.Abramson MA, Swanson EW, Whang EE. Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis. J Gastrointest Surg. 2009;13(1):26-34.

213.Porembka MR, Hawkins WG, Linehan DC, Gao F, Ma C, Brunt EM, et al. Radiologic and intraoperative detection of need for mesenteric vein resection in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford). 2011;13(9):633-42.

214.Siriwardana HP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg. 2006;93(6):662-73.

215.Michalski CW, Erkan M, Huser N, Muller MW, Hartel M, Friess H, et al. Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg. 2008;25(6):473-80.

216.Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110(11):2484-92.

217.Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14(1):118-27.

218.Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg. 2002;6(2):147-57; discussion 57-8.

219.Shrikhande SV, Barreto SG. Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence. World J Gastrointest Surg. 2010;2(2):39-46.

220.Hartwig W, Hackert T, Hinz U, Hassenpflug M, Strobel O, Buchler MW, et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg. 2009;250(1):81-7.

221.Burdelski CM, Reeh M, Bogoevski D, Gebauer F, Tachezy M, Vashist YK, et al. Multivisceral resections in pancreatic cancer: identification of risk factors. World J Surg. 2011;35(12):2756-63.

222.Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576-85.

223.Fischer M, Matsuo K, Gonen M, Grant F, Dematteo RP, D'Angelica MI, et al. Relationship between intraoperative fluid administration and perioperative outcome after pancreaticoduodenectomy: results of a prospective randomized trial of acute normovolemic hemodilution compared with standard intraoperative management. Ann Surg. 2010;252(6):952-8.

224.Welsch T, Borm M, Degrate L, Hinz U, Buchler MW, Wente MN. Evaluation of the International Study Group of Pancreatic Surgery definition of delayed gastric emptying after pancreatoduodenectomy in a high-volume centre. Br J Surg. 2010;97(7):1043-50.

225.Lu X, Wang X, Fang Y, Chen H, Peng C, Li H, et al. Systematic Review and Meta-Analysis of Pancreatic Amylase Value on Postoperative Day 1 After Pancreatic Resection to Predict Postoperative Pancreatic Fistula. Medicine (Baltimore). 2016;95(5):e2569.

226.Muscari F, Suc B, Kirzin S, Hay JM, Fourtanier G, Fingerhut A, et al. Risk factors for mortality and intra-abdominal complications after pancreatoduodenectomy: multivariate analysis in 300 patients. Surgery. 2006;139(5):591-8.

227.Liang TB, Bai XL, Zheng SS. Pancreatic fistula after pancreaticoduodenectomy: diagnosed according to International Study Group Pancreatic Fistula (ISGPF) definition. Pancreatology. 2007;7(4):325-31.

228.Shimoda M, Katoh M, Yukihiro I, Kita J, Sawada T, Kubota K. Body mass index is a risk factor of pancreatic fistula after pancreaticoduodenectomy. Am Surg. 2012;78(2):190-4.

229.Ansorge C, Strommer L, Andren-Sandberg A, Lundell L, Herrington MK, Segersvard R. Structured intraoperative assessment of pancreatic gland characteristics in predicting complications after pancreaticoduodenectomy. Br J Surg. 2012;99(8):1076-82.

230.Frozanpor F, Loizou L, Ansorge C, Segersvard R, Lundell L, Albiin N. Preoperative pancreas CT/MRI characteristics predict fistula rate after pancreaticoduodenectomy. World J Surg. 2012;36(8):1858-65.

231.Kaminsky PM, Mezhir JJ. Intraperitoneal drainage after pancreatic resection: a review of the evidence. J Surg Res. 2013;184(2):925-30.

232.Cecka F, Lovecek M, Jon B, Skalicky P, Subrt Z, Neoral C, et al. Intra-abdominal drainage following pancreatic resection: A systematic review. World J Gastroenterol. 2015;21(40):11458-68.

233.Conlon KC, Labow D, Leung D, Smith A, Jarnagin W, Coit DG, et al. Prospective randomized clinical trial of the value of intraperitoneal drainage after pancreatic resection. Ann Surg. 2001;234(4):487-93; discussion 93-4.

234.Mahvi D. Defining, controlling, and treating a pancreatic fistula. J Gastrointest Surg. 2009;13(7):1187-8.

235.Roulin D, Cerantola Y, Demartines N, Schafer M. Systematic review of delayed postoperative hemorrhage after pancreatic resection. J Gastrointest Surg. 2011;15(6):1055-62.

236.Coupland VH, Konfortion J, Jack RH, Allum W, Kocher HM, Riaz SP, et al. Resection rate, hospital procedure volume and survival in pancreatic cancer patients in England: Population-based study, 2005-2009. Eur J Surg Oncol. 2016;42(2):190-6.

237.Finlayson EV, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: a national study. Arch Surg. 2003;138(7):721-5; discussion 6.

238.Finlayson EV, Birkmeyer JD. Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis. J Am Coll Surg. 2003;196(3):410-7.

239.Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245(5):777-83.

240.Williamsson C, Karlsson N, Sturesson C, Lindell G, Andersson R, Tingstedt B. Impact of a fast-track surgery programme for pancreaticoduodenectomy. Br J Surg. 2015;102(9):1133-41.

241.Andren-Sandberg A, Wagner M, Tihanyi T, Lofgren P, Friess H. Technical aspects of left-sided pancreatic resection for cancer. Dig Surg. 1999;16(4):305-12.

242.Matsuoka L, Selby R, Genyk Y. The surgical management of pancreatic cancer. Gastroenterol Clin North Am. 2012;41(1):211-21.

243.Kim SC, Kim YH, Park KM, Lee YJ. Pancreatic cancer surgery: the state of the art. Curr Drug Targets. 2012;13(6):764-71.

244.Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8-13.

245.Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161(3):584-91.

246.Diener MK, Seiler CM, Rossion I, Kleeff J, Glanemann M, Butturini G, et al. Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet. 2011;377(9776):1514-22.

247.Hamilton NA, Porembka MR, Johnston FM, Gao F, Strasberg SM, Linehan DC, et al. Mesh reinforcement of pancreatic transection decreases incidence of pancreatic occlusion failure for left pancreatectomy: a single-blinded, randomized controlled trial. Ann Surg. 2012;255(6):1037-42.

248.Probst P, Huttner FJ, Klaiber U, Knebel P, Ulrich A, Buchler MW, et al. Stapler versus scalpel resection followed by hand-sewn closure of the pancreatic remnant for distal pancreatectomy. Cochrane Database Syst Rev. 2015(11):CD008688.

249.Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003;133(5):521-7.

250.Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg. 2007;204(2):244-9.

251.Zhou Y, Shi B, Wu L, Si X. A systematic review of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. HPB (Oxford). 2017;19(1):10-5.

252.Trottman P, Swett K, Shen P, Sirintrapun J. Comparison of standard distal pancreatectomy and splenectomy with radical antegrade modular pancreatosplenectomy. Am Surg. 2014;80(3):295-300.

253.Abe T, Ohuchida K, Miyasaka Y, Ohtsuka T, Oda Y, Nakamura M. Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sided Pancreatic Cancer. World J Surg. 2016;40(9):2267-75.

254.Appelby. The coeliac axis in the expansion of the operation for gastric carcinoma. Cancer. 1953;6(4):704-7.

255.Latona JA, Lamb KM, Pucci MJ, Maley WR, Yeo CJ. Modified Appleby Procedure with Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma: A Literature Review and Report of Three Unusual Cases. J Gastrointest Surg. 2016;20(2):300-6.

256.Gong H, Ma R, Gong J, Cai C, Song Z, Xu B. Distal Pancreatectomy With En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016;95(10):e3061.

257.Nakamura T, Hirano S, Noji T, Asano T, Okamura K, Tsuchikawa T, et al. Distal Pancreatectomy with en Bloc Celiac Axis Resection (Modified Appleby Procedure) for Locally Advanced Pancreatic Body Cancer: A Single-Center Review of 80 Consecutive Patients. Ann Surg Oncol. 2016;23(Suppl 5):969-75.

258.Smoot RL, Donohue JH. Modified Appleby procedure for resection of tumors of the pancreatic body and tail with celiac axis involvement. J Gastrointest Surg. 2012;16(11):2167-9.

259.Strasberg SM, Fields R. Left-sided pancreatic cancer: distal pancreatectomy and its variants: radical antegrade modular pancreatosplenectomy and distal pancreatectomy with celiac axis resection. Cancer J. 2012;18(6):562-70.

260.Beane JD, House MG, Pitt SC, Kilbane EM, Hall BL, Parmar AD, et al. Distal pancreatectomy with celiac axis resection: what are the added risks? HPB (Oxford). 2015;17(9):777-84.

261.Johnston WC, Hoen HM, Cassera MA, Newell PH, Hammill CW, Hansen PD, et al. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base. HPB (Oxford). 2016;18(1):21-8.

262.Billings BJ, Christein JD, Harmsen WS, Harrington JR, Chari ST, Que FG, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg. 2005;9(8):1059-66; discussion 66-7.

263.Santangelo M, Esposito A, Tammaro V, Calogero A, Criscitiello C, Roberti G, et al. What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. Int J Surg. 2016;28 Suppl 1:S172-6.

264.Mabrut JY, Fernandez-Cruz L, Azagra JS, Bassi C, Delvaux G, Weerts J, et al. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery. 2005;137(6):597-605.

265.Kooby DA, Gillespie T, Bentrem D, Nakeeb A, Schmidt MC, Merchant NB, et al. Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg. 2008;248(3):438-46.

266.Riviere D, Gurusamy KS, Kooby DA, Vollmer CM, Besselink MG, Davidson BR, et al. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Cochrane Database Syst Rev. 2016;4:CD011391.

267.Wellner UF, Lapshyn H, Bartsch DK, Mintziras I, Hopt UT, Wittel U, et al. Laparoscopic versus open distal pancreatectomy-a propensity score-matched analysis from the German StuDoQ|Pancreas registry. Int J Colorectal Dis. 2017;32(2):273-80.

268.Gumbs AA, Rodriguez Rivera AM, Milone L, Hoffman JP. Laparoscopic pancreatoduodenectomy: a review of 285 published cases. Ann Surg Oncol. 2011;18(5):1335-41.

269.Coppola A, Stauffer JA, Asbun HJ. Laparoscopic pancreatoduodenectomy: current status and future directions. Updates Surg. 2016;68(3):217-24.

270.Kauffmann EF, Napoli N, Menonna F, Vistoli F, Amorese G, Campani D, et al. Robotic pancreatoduodenectomy with vascular resection. Langenbecks Arch Surg. 2016;401(8):1111-22.

271.Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496-502.

272.Lind PA, Isaksson B, Almstrom M, Johnsson A, Albiin N, Bystrom P, et al. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol. 2008;47(3):413-20.

273.Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844-53.

274.Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-77.

275.Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-10.

276.Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147-56.

277.Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248-57.

278.Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-24.

279.Gouma DJ, Busch OR, Van Gulik TM. Pancreatic carcinoma: palliative surgical and endoscopic treatment. HPB (Oxford). 2006;8(5):369-76.

280.Jeurnink SM, Steyerberg EW, Vleggaar FP, van Eijck CH, van Hooft JE, Schwartz MP, et al. Predictors of survival in patients with malignant gastric outlet obstruction: a patient-oriented decision approach for palliative treatment. Dig Liver Dis. 2011;43(7):548-52.

281.Gillen S, Schuster T, Friess H, Kleeff J. Palliative resections versus palliative bypass procedures in pancreatic cancer--a systematic review. Am J Surg. 2012;203(4):496-502.

282.Tol JA, Eshuis WJ, Besselink MG, van Gulik TM, Busch OR, Gouma DJ. Non-radical resection versus bypass procedure for pancreatic cancer - a consecutive series and systematic review. Eur J Surg Oncol. 2015;41(2):220-7.

283.Insulander J, Sanjeevi S, Haghighi M, Ivanics T, Analatos A, Lundell L, et al. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma. Br J Surg. 2016;103(9):1200-8.

284.Williamsson C, Wennerblom J, Tingstedt B, Jonsson C. A wait-and-see strategy with subsequent self-expanding metal stent on demand is superior to prophylactic bypass surgery for unresectable periampullary cancer. HPB (Oxford). 2016;18(1):107-12.

285.Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev. 2006(1):CD004200.

286.Muller MW, Friess H, Koninger J, Martin D, Wente MN, Hinz U, et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg. 2008;195(2):221-8.

287.Moss. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane review 2010; 2010:11.

288.Maire F, Sauvanet A. Palliation of biliary and duodenal obstruction in patients with unresectable pancreatic cancer: endoscopy or surgery? J Visc Surg. 2013;150(3 Suppl):S27-31.

289.Glazer ES, Hornbrook MC, Krouse RS. A meta-analysis of randomized trials: immediate stent placement vs. surgical bypass in the palliative management of malignant biliary obstruction. J Pain Symptom Manage. 2014;47(2):307-14.

290.Watanapa P, Williamson RC. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg. 1992;79(1):8-20.

291.Wong YT, Brams DM, Munson L, Sanders L, Heiss F, Chase M, et al. Gastric outlet obstruction secondary to pancreatic cancer: surgical vs endoscopic palliation. Surg Endosc. 2002;16(2):310-2.

292.Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg. 1999;230(3):322-8; discussion 8-30.

293.Van Heek NT, De Castro SM, van Eijck CH, van Geenen RC, Hesselink EJ, Breslau PJ, et al. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg. 2003;238(6):894-902; discussion -5.

294.Gurusamy KS, Kumar S, Davidson BR. Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. Cochrane Database Syst Rev. 2010(10):CD008533.

295.Spanheimer PM, Cyr AR, Liao J, Johlin FC, Hoshi H, Howe JR, et al. Complications and survival associated with operative procedures in patients with unresectable pancreatic head adenocarcinoma. J Surg Oncol. 2014;109(7):697-701.

296.Lowe AS, Beckett CG, Jowett S, May J, Stephenson S, Scally A, et al. Self-expandable metal stent placement for the palliation of malignant gastroduodenal obstruction: experience in a large, single, UK centre. Clin Radiol. 2007;62(8):738-44.

297.Mutignani M, Tringali A, Shah SG, Perri V, Familiari P, Iacopini F, et al. Combined endoscopic stent insertion in malignant biliary and duodenal obstruction. Endoscopy. 2007;39(5):440-7.

298.Kim JH, Song HY, Shin JH, Choi E, Kim TW, Jung HY, et al. Metallic stent placement in the palliative treatment of malignant gastroduodenal obstructions: prospective evaluation of results and factors influencing outcome in 213 patients. Gastrointest Endosc. 2007;66(2):256-64.

299.Maetani I, Isayama H, Mizumoto Y. Palliation in patients with malignant gastric outlet obstruction with a newly designed enteral stent: a multicenter study. Gastrointest Endosc. 2007;66(2):355-60.

300.Dormann A, Meisner S, Verin N, Wenk Lang A. Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy. 2004;36(6):543-50.

301.Larssen L, Medhus AW, Hauge T. Treatment of malignant gastric outlet obstruction with stents: an evaluation of the reported variables for clinical outcome. BMC Gastroenterol. 2009;9:45.

302.Espinel J, Sanz O, Vivas S, Jorquera F, Munoz F, Olcoz JL, et al. Malignant gastrointestinal obstruction: endoscopic stenting versus surgical palliation. Surg Endosc. 2006;20(7):1083-7.

303.Holt AP, Patel M, Ahmed MM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc. 2004;60(6):1010-7.

304.Johnsson E, Thune A, Liedman B. Palliation of malignant gastroduodenal obstruction with open surgical bypass or endoscopic stenting: clinical outcome and health economic evaluation. World J Surg. 2004;28(8):812-7.

305.Mittal A, Windsor J, Woodfield J, Casey P, Lane M. Matched study of three methods for palliation of malignant pyloroduodenal obstruction. Br J Surg. 2004;91(2):205-9.

306.Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049-57.

307.Walter D, van Boeckel PG, Groenen MJ, Weusten BL, Witteman BJ, Tan G, et al. Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial. Gastroenterology. 2015;149(1):130-8.

308.Almadi MA, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(1):27-37 e1.

309.Moole H, Bechtold ML, Cashman M, Volmar FH, Dhillon S, Forcione D, et al. Covered versus uncovered self-expandable metal stents for malignant biliary strictures: A meta-analysis and systematic review. Indian J Gastroenterol. 2016;35(5):323-30.

310.Briggs CD, Irving GR, Cresswell A, Peck R, Lee F, Peterson M, et al. Percutaneous transhepatic insertion of self-expanding short metal stents for biliary obstruction before resection of pancreatic or duodenal malignancy proves to be safe and effective. Surg Endosc. 2010;24(3):567-71.

311.Mahgerefteh S, Hubert A, Klimov A, Bloom AI. Clinical Impact of Percutaneous Transhepatic Insertion of Metal Biliary Endoprostheses for Palliation of Jaundice and Facilitation of Chemotherapy. Am J Clin Oncol. 2015;38(5):489-94.

312.Kunda R, Perez-Miranda M, Will U, Ullrich S, Brenke D, Dollhopf M, et al. EUS-guided choledochoduodenostomy for malignant distal biliary obstruction using a lumen-apposing fully covered metal stent after failed ERCP. Surg Endosc. 2016;30(11):5002-8.

313.van Halsema EE, Rauws EA, Fockens P, van Hooft JE. Self-expandable metal stents for malignant gastric outlet obstruction: A pooled analysis of prospective literature. World J Gastroenterol. 2015;21(43):12468-81.

314.Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Kawakubo K, et al. Predictive factors of solid food intake in patients with malignant gastric outlet obstruction receiving self-expandable metallic stents for palliation. Dig Endosc. 2012;24(4):226-30.

315.Hori Y, Naitoh I, Hayashi K, Ban T, Natsume M, Okumura F, et al. Predictors of outcomes in patients undergoing covered and uncovered self-expandable metal stent placement for malignant gastric outlet obstruction: a multicenter study. Gastrointest Endosc. 2017;85(2):340-8 e1.

316.Costamagna G, Tringali A, Spicak J, Mutignani M, Shaw J, Roy A, et al. Treatment of malignant gastroduodenal obstruction with a nitinol self-expanding metal stent: an international prospective multicentre registry. Dig Liver Dis. 2012;44(1):37-43.

317.Lee KM, Choi SJ, Shin SJ, Hwang JC, Lim SG, Jung JY, et al. Palliative treatment of malignant gastroduodenal obstruction with metallic stent: prospective comparison of covered and uncovered stents. Scand J Gastroenterol. 2009;44(7):846-52.

318.Maetani I, Mizumoto Y, Shigoka H, Omuta S, Saito M, Tokuhisa J, et al. Placement of a triple-layered covered versus uncovered metallic stent for palliation of malignant gastric outlet obstruction: a multicenter randomized trial. Dig Endosc. 2014;26(2):192-9.

319.Kim CG, Choi IJ, Lee JY, Cho SJ, Park SR, Lee JH, et al. Covered versus uncovered self-expandable metallic stents for palliation of malignant pyloric obstruction in gastric cancer patients: a randomized, prospective study. Gastrointest Endosc. 2010;72(1):25-32.

320.van Hooft JE, Uitdehaag MJ, Bruno MJ, Timmer R, Siersema PD, Dijkgraaf MG, et al. Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc. 2009;69(6):1059-66.

321.Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008;44(8):1105-15.

322.Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592-9.

323.Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25(18):2607-15.

324.Lidestahl A, Permert J, Linder S, Bylund H, Edsborg N, Lind P. Reassessment for radical surgery after palliative chemotherapy in locally advanced pancreatic carcinoma: two case-reports. Acta Oncol. 2006;45(2):210-2.

325.Conroy T, Yataghene Y, Etienne PL, Michel P, Senellart H, Raoul JL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer. 2010;103(9):1349-55.

326.Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703.

327.Boeck. Gemcitabine plus erlotinib followed by capecitabine versus capecitabibe plus erlotinib followed by gemcitabine in advanced pancreatic cancer: A randomized, cross over phase II trial of the AIO. J Clin Oncol 2010;28:(18s suppl):LBA 4011.

328.Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, Emerich J, et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer. 2005;104(5):1004-12.

329.Oliver G. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma(abstract). ASCO Gastrointestinal Cancer Symposium 2010:180:2010.

330.Pelzer. A randomized trial in patients with gemcitabine refractory pancreatic cancer final result of the CONKO 003 study. J Clin Oncol. 2008;26:4508.

331.Pehr Lind: Gill. Journal of Clinical Oncology 34, no. 32 (November 2016) 3914-3920.

332.Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-81.

333.Morrison M. Post-pancreatic resection: general overview and unique complications. Dimens Crit Care Nurs. 2010;29(4):157-62.

334.Hathaway D. Effect of preoperative instruction on postoperative outcomes: a meta-analysis. Nurs Res. 1986;35(5):269-75.

335.Ayyadhah Alanazi A. Reducing anxiety in preoperative patients: a systematic review. Br J Nurs. 2014;23(7):387-93.

336.Kelly L, Vincent D. The dimensions of nursing surveillance: a concept analysis. J Adv Nurs. 2011;67(3):652-61.

337.Smith GB, Prytherch DR, Meredith P, Schmidt PE, Featherstone PI. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. Resuscitation. 2013;84(4):465-70.

338.Spangfors M, Arvidsson L, Karlsson V, Samuelson K. The National Early Warning Score: Translation, testing and prediction in a Swedish setting. Intensive Crit Care Nurs. 2016;37:62-7.

339.Varadhan KK, Lobo DN. A meta-analysis of randomised controlled trials of intravenous fluid therapy in major elective open abdominal surgery: getting the balance right. Proc Nutr Soc. 2010;69(4):488-98.

340.Coolsen MM, van Dam RM, van der Wilt AA, Slim K, Lassen K, Dejong CH. Systematic review and meta-analysis of enhanced recovery after pancreatic surgery with particular emphasis on pancreaticoduodenectomies. World J Surg. 2013;37(8):1909-18.

341.Fredericks S, Guruge S, Sidani S, Wan T. Postoperative patient education: a systematic review. Clin Nurs Res. 2010;19(2):144-64.

342.Socialdepartementet. kriterier som skall utmärka regionala cancercentrum. wwwregeringense/sb/d/14025/a/160525. 2011-01-31.

343.http://cancercentrum.se/globalassets/vara-uppdrag/vardprocesser/vast/cancervardprocessen/bakgrundsmaterial/6.1.1-distresstermometern.pdf.

344.Socialstyrelsen. Din Skyldighet att informera och göra patienten delaktig Socialstyrelsen. 2012;ISBN: 978-91-86885-98-4.

345.Sjuksköterskeförening SiCS. Kompetensbeskrivning legitimerad sjuksköterska med specialistsjuksköterskeexamen med inriktning mot onkologisk vård. Stockholm Åtta 45. 2009.

346.Kontaktsjuksköterska. (http://www.skl.se/vi_arbetar_med/halsaochvard/cancervard/utvecklingsarbeten_cancervard/kontaktsjukskoterska ). SKL Sveriges Kommuner och Landsting. 2012.

347.Heye T, Zausig N, Klauss M, Singer R, Werner J, Richter GM, et al. CT diagnosis of recurrence after pancreatic cancer: is there a pattern? World J Gastroenterol. 2011;17(9):1126-34.

348.Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35(6):600-4.

349.Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10(4):511-8.

350.Koizumi M, Sata N, Kasahara N, Morishima K, Sasanuma H, Sakuma Y, et al. Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports. JOP. 2010;11(1):36-40.

351.Miyazaki M, Yoshitomi H, Shimizu H, Ohtsuka M, Yoshidome H, Furukawa K, et al. Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile? Surgery. 2014;155(1):58-66.

352.Shimoike N, Fujikawa T, Maekawa H, Tanaka A. Aggressive secondary surgery for local recurrence of pancreatic cancer. BMJ Case Rep. 2013;2013.

353.Shima Y, Okabayashi T, Kozuki A, Sumiyoshi T, Tokumaru T, Saisaka Y, et al. Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature. Langenbecks Arch Surg. 2015;400(8):973-8.

354.Seelig MH, Janot M, Chromik AM, Herzog T, Belyaev O, Weyhe D, et al. Redo-surgery following curative resection of pancreatic carcinoma: the difference between true and suspected recurrence. Dig Surg. 2009;26(3):222-8.

355.Dunschede F, Will L, von Langsdorf C, Mohler M, Galle PR, Otto G, et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res. 2010;44(3-4):209-13.

356.Mueller TC, Burmeister MA, Bachmann J, Martignoni ME. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol. 2014;20(28):9361-73.

357.Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Buchler MW, et al. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer. 2009;9:255.

358.Baldwin C, Weekes CE. Dietary counselling with or without oral nutritional supplements in the management of malnourished patients: a systematic review and meta-analysis of randomised controlled trials. J Hum Nutr Diet. 2012;25(5):411-26.

359.McClave SA, Kozar R, Martindale RG, Heyland DK, Braga M, Carli F, et al. Summary points and consensus recommendations from the North American Surgical Nutrition Summit. JPEN J Parenter Enteral Nutr. 2013;37(5 Suppl):99S-105S.

360.Morgan KA, Lancaster WP, Walters ML, Owczarski SM, Clark CA, McSwain JR, et al. Enhanced Recovery After Surgery Protocols Are Valuable in Pancreas Surgery Patients. J Am Coll Surg. 2016;222(4):658-64.

361.Gerritsen A, Besselink MG, Gouma DJ, Steenhagen E, Borel Rinkes IH, Molenaar IQ. Systematic review of five feeding routes after pancreatoduodenectomy. Br J Surg. 2013;100(5):589-98; discussion 99.

362.Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142(5):761-8.

363.Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2016.

364.Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013;19(42):7258-66.

365.Sabater L, Ausania F, Bakker OJ, Boadas J, Dominguez-Munoz JE, Falconi M, et al. Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Ann Surg. 2016;264(6):949-58.

366.Benini L, Amodio A, Campagnola P, Agugiaro F, Cristofori C, Micciolo R, et al. Fecal elastase-1 is useful in the detection of steatorrhea in patients with pancreatic diseases but not after pancreatic resection. Pancreatology. 2013;13(1):38-42.

367.Tseng DS, Molenaar IQ, Besselink MG, van Eijck CH, Borel Rinkes IH, van Santvoort HC. Pancreatic Exocrine Insufficiency in Patients With Pancreatic or Periampullary Cancer: A Systematic Review. Pancreas. 2016;45(3):325-30.

368.Bruno MJ, Haverkort EB, Tijssen GP, Tytgat GN, van Leeuwen DJ. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998;42(1):92-6.

369.Woo SM, Joo J, Kim SY, Park SJ, Han SS, Kim TH, et al. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Pancreatology. 2016;16(6):1099-105.

370.Seiler CM, Izbicki J, Varga-Szabo L, Czako L, Fiok J, Sperti C, et al. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension. Aliment Pharmacol Ther. 2013;37(7):691-702.

371.Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Vilarino-Insua M. Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts. Gut. 2006;55(7):1056-7.

372.Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928-37.

373.Lu Y, Garcia Rodriguez LA, Malgerud L, Gonzalez-Perez A, Martin-Perez M, Lagergren J, et al. New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. Br J Cancer. 2015;113(11):1607-14.

374.Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981-7.

375.Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. 2013;42(2):198-201.

376.He XY, Li JF, Yao WY, Yuan YZ. Resolution of new-onset diabetes after radical pancreatic resection predicts long-term survival in patients with pancreatic ductal cell adenocarcinoma. Ann Surg Oncol. 2013;20(12):3809-16.

377.Eshuis WJ, Hermanides J, van Dalen JW, van Samkar G, Busch OR, van Gulik TM, et al. Early postoperative hyperglycemia is associated with postoperative complications after pancreatoduodenectomy. Ann Surg. 2011;253(4):739-44.

378.Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology. 2011;11(3):279-94.

379.Makuc J. Management of pancreatogenic diabetes: challenges and solutions. Diabetes Metab Syndr Obes. 2016;9:311-5.

380.King EJ, Haboubi H, Evans D, Baker I, Bain SC, Stephens JW. The management of diabetes in terminal illness related to cancer. QJM. 2012;105(1):3-9.

381.Munshi MN, Florez H, Huang ES, Kalyani RR, Mupanomunda M, Pandya N, et al. Management of Diabetes in Long-term Care and Skilled Nursing Facilities: A Position Statement of the American Diabetes Association. Diabetes Care. 2016;39(2):308-18.

382.Läkemedelsboken. kapitlet Smärta och palliativ vård: http://www.lakemedelsverket.se/lakemedelsboken. Läkemedelsboken. 2012-13.

383.Palliativvårdprogram. Nationellt vårdprogram för Palliativ vård 2012-2014: http://www.skl.se/vi_arbetar_med/halsaochvard/cancervard/utvecklingsarbeten_cancervard/nationella-vardprogram.

384.Stocholm-Gotland R. Nationellt vårdprogram för palliativ vård. http://www.skl.se/MediaBinaryLoader.axd?MediaArchive_FileID=690ec782-07e3-4dd2-bbad-ab98420fa248&FileName=NatVP_Palliativv%c3%a5rd_2012_final.pdf2012.

385.Jia L, Shang YY, Jiang SM, Xie Q, Huang YX, Xie DR, et al. [Relationship between symptoms of pancreatic cancer-related depression and quality of life of patients]. Zhonghua Yi Xue Za Zhi. 2009;89(26):1847-9.

386.Lundstrom SH, Furst CJ. The use of corticosteroids in Swedish palliative care. Acta Oncol. 2006;45(4):430-7.

387.Barnes EA, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer. 2002;12(5):424-8.

388.Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2008(2):CD006145.

389.Läkemedelsverket. Smärtlindring i livets slutskede: ny rekommendation. 2010. Sverige Läkemedelsverket, Smärtlindring i livets slutskede: ny rekommendation 2010, Uppsala: Läkemedelsverket 38 s. 2010;Sverige. Uppsala: Läkemedelsverket. : 38 s.

390.Mercadante S, Tirelli W, David F, Arcara C, Fulfaro F, Casuccio A, et al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain. 2010;26(9):794-7.

391.Mercadante S, Catala E, Arcuri E, Casuccio A. Celiac plexus block for pancreatic cancer pain: factors influencing pain, symptoms and quality of life. J Pain Symptom Manage. 2003;26(6):1140-7.

392.Teshima CW, Sandha GS. Endoscopic ultrasound in the diagnosis and treatment of pancreatic disease. World J Gastroenterol. 2014;20(29):9976-89.

393.Wells M, Macmillan M, Raab G, MacBride S, Bell N, MacKinnon K, et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol. 2004;73(2):153-62.

394.Iwakawa M, Noda S, Yamada S, Yamamoto N, Miyazawa Y, Yamazaki H, et al. Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer. 2006;13(3):300-7.

395.Sharp L, Johansson H, Hatschek T, Bergenmar M. Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast. 2013;22(5):634-8.

396.Prochazka M, Granath F, Ekbom A, Shields PG, Hall P. Lung cancer risks in women with previous breast cancer. Eur J Cancer. 2002;38(11):1520-5.

397.Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109(4):650-7.

398.Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol. 2008;26(3):392-8.

399.Macdonald G, Kondor N, Yousefi V, Green A, Wong F, Aquino-Parsons C. Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol. 2004;73(3):367-71.

400.Peterson C. [Natural remedies--self care at your own risk! Danger of unknown adverse effects and interactions with "common" medications]. Lakartidningen. 2005;102(44):3200-1.

401.Malekzadeh F, Rose C, Ingvar C, Jernstrom H. [Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment]. Lakartidningen. 2005;102(44):3226-8, 30-1.

402.Tonnesen H, Nielsen PR, Lauritzen JB, Moller AM. Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth. 2009;102(3):297-306.

403.Nath B, Li Y, Carroll JE, Szabo G, Tseng JF, Shah SA. Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg. 2010;14(11):1732-41.

404.Bradley KA, Rubinsky AD, Sun H, Bryson CL, Bishop MJ, Blough DK, et al. Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med. 2011;26(2):162-9.

405.Sundhedsstyrelsen. pakkeforlöb for kraeft i bugspytkirtlen. In: Sygehusbehandling och beredskap Smssd, editor. 2012.

406.Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395-401.

407.Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg. 1995;222(5):638-45.

408.Sosa JA, Bowman HM, Gordon TA, Bass EB, Yeo CJ, Lillemoe KD, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg. 1998;228(3):429-38.

409.Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128-37.

410.Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000;232(6):786-95.

411.Kotwall CA, Maxwell JG, Brinker CC, Koch GG, Covington DL. National estimates of mortality rates for radical pancreaticoduodenectomy in 25,000 patients. Ann Surg Oncol. 2002;9(9):847-54.

412.van Heek NT, Kuhlmann KF, Scholten RJ, de Castro SM, Busch OR, van Gulik TM, et al. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg. 2005;242(6):781-8, discussion 8-90.

413.Birkmeyer NJ, Goodney PP, Stukel TA, Hillner BE, Birkmeyer JD. Do cancer centers designated by the National Cancer Institute have better surgical outcomes? Cancer. 2005;103(3):435-41.

414.Fong Y, Gonen M, Rubin D, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg. 2005;242(4):540-4; discussion 4-7.

415.Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117-27.

416.Eppsteiner RW, Csikesz NG, McPhee JT, Tseng JF, Shah SA. Surgeon volume impacts hospital mortality for pancreatic resection. Ann Surg. 2009;249(4):635-40.

417.Schmidt CM, Turrini O, Parikh P, House MG, Zyromski NJ, Nakeeb A, et al. Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience. Arch Surg. 2010;145(7):634-40.

418.Tseng JF, Pisters PW, Lee JE, Wang H, Gomez HF, Sun CC, et al. The learning curve in pancreatic surgery. Surgery. 2007;141(4):456-63.

419.Ghaferi AA, Osborne NH, Birkmeyer JD, Dimick JB. Hospital characteristics associated with failure to rescue from complications after pancreatectomy. J Am Coll Surg. 2010;211(3):325-30.

420.Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and failure to rescue with high-risk surgery. Med Care. 2011;49(12):1076-81.

421.Goodney PP, Stukel TA, Lucas FL, Finlayson EV, Birkmeyer JD. Hospital volume, length of stay, and readmission rates in high-risk surgery. Ann Surg. 2003;238(2):161-7.

422.Riall TS, Nealon WH, Goodwin JS, Townsend CM, Jr., Freeman JL. Outcomes following pancreatic resection: variability among high-volume providers. Surgery. 2008;144(2):133-40.

423.Eppsteiner RW, Csikesz NG, Simons JP, Tseng JF, Shah SA. High volume and outcome after liver resection: surgeon or center? J Gastrointest Surg. 2008;12(10):1709-16; discussion 16.

424.Ihse I. The volume-outcome relationship in cancer surgery: a hard sell. Ann Surg. 2003;238(6):777-81.

425.NHS. Guidance on commissioning cancer services. Improving the outcomes in upper gastro-intestinal cancers. NHS Executive2001.

426.Riall TS, Eschbach KA, Townsend CM, Jr., Nealon WH, Freeman JL, Goodwin JS. Trends and disparities in regionalization of pancreatic resection. J Gastrointest Surg. 2007;11(10):1242-51; discussion 51-2.

427.Socialstyrelsen. http://www.socialstyrelsen.se/publikationer2007/2007-102-9 2012.           .

428.RCCsamverkan. Styrdokument - riktlinjer för nationella vårdprogram inom cancervården 2012. http://www.cancercentrum.se/PageFiles/2797/Riktlinjer_natVP_final.pdf].